While purchasing medicine - It is important that you let us know what other medicine you are using.
This is for preventing unwanted drug interactions.


Want to ask us a professional question ? Call us or Connect VIA Skype





Skype Me™! 
 



 
 
 
 

SANDOSTATIN LAR
Home >> Search Drug By Letter >> Search Drug By Letter: S >> SANDOSTATIN LAR
Search Drug By Letter : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

SANDOSTATIN LAR
 
Package(a):
VIALS: 1 x 10 mg (2 vehicle ampoules + 1 injection set).
Dosage(a):
By deep intragluteal injection. See prescribing information for full details.
Prescribing RestrictionsKupah Pharmacy Only Medical Division Approval 

Package(b):
VIALS: 1 x 20 mg (2 vehicle ampoules + 1 injection set).
Dosage(b):
By deep intragluteal injection. See prescribing information for full details.
Prescribing RestrictionsKupah Pharmacy Only Medical Division Approval 
 
Package(c):
VIALS: 1 x 30 mg (2 vehicle ampoules + 1 injection set).
Dosage(c):
By deep intragluteal injection. See prescribing information for full details.
Prescribing RestrictionsKupah Pharmacy Only Medical Division Approval 

Package(d):
PREFILLED SYRINGE (with solvent for parenteral use): 1 x 10 mg + 2 needles.
Dosage(d):
See prescribing information for full details.
Prescribing Restrictions:  None

Package(e):
PREFILLED SYRINGE (with solvent for parenteral use): 1 x 20 mg + 2 needles.
Dosage(e):
See prescribing information for full details.
Prescribing Restrictions:  None

Package(f):
PREFILLED SYRINGE (with solvent for parenteral use): 1 x 30 mg + 2 needles.
Dosage(f):
See prescribing information for full details.
Prescribing Restrictions:  None


Indications:
Treatment of patients with acromegaly who are adequately controlled on S.C. treatment with Sandostatin; in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective. 
Treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumors in whom symptoms are adequately controlled on S.C. treatment with Sandostatin. 
Carcinoid tumors with features of the carcinoid syndrome, VIPomas, glucagonomas, gastrinomas/Zollinger-Ellison syndrome, insulinomas, for pre-operative control of hypoglycemia and for maintenance therapy, GRFomas.
Contra-Indications:
Hypersensitivity to octreotide or any of components of the formulation.
Special Precautions:
As GH-secreting pituitary tumors may sometimes expand, causing serious complications, it is essential that all patients be carefully monitored. If evidence of expansion appears, alternative procedures are advisable. Development of gallstones has been reported in 15-30% of long-term recipients of S.C. Sandostatin. Ultrasonic examination of the gallbladder before and at about 6-monthly intervals during therapy is however recommended. In patients with concomitant type I diabetes mellitus, treatment is likely to affect glucose regulation, and insulin requirements may be reduced. In non-diabetics and type II diabetics with partially intact insulin reserves, administration may result in increases in post-prandial glycemia. Glucose tolerance and antidiabetic treatment should therefore be monitored. In patients with insulinomas, octreotide may increase the depth and prolong the duration of hypoglycemia. Patients should be closely monitored. 
Pregnancy and lactation: Should be given only under compelling circumstances.
Side Effects:
Gallstone formation. Anorexia, nausea, vomiting, crampy abdominal pain, abdominal bloating, flatulence, loose stools, diarrhea, steatorrhea. Hyperglycemia, hypoglycaemia.
Drug Interactions:
Cyclosporin, cimetidine, hypoglycemics. Bromocriptine, beta blockers, calcium channel blockers, agents to control fluid and electrolyte balance.